Company: DAWN
Filing Date: 2025-10-10
Form Type: 8-K
Source: 0001193125-25-237072
Chunk: 1

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-10-10
Form: 8-K
Item: Item 5.02
Chunk 1
---
 hold the following aggregate number of repriced options: Jeremy Bender, Ph. D., M. B. A., President and Chief Executive Officer: 2,676,134 repriced options, with original exercise prices ranging from $11.87 to $23.41; Charles York, M. B. A., Chief Operating Officer and Chief Financial Officer: 1,088,667 repriced options, with original exercise prices ranging from $11.87 to $23.41; and Adam Dubow, General Counsel, Chief Compliance Officer and Secretary: 270,000 repriced options, with original exercise prices ranging from $11.87 to $23.41. In addition, Mr. Dubow held an inducement grant with an exercise price of $21.14 which was not eligible for the Repricing and the Compensation Committee approved a stock option of 309,000 shares which will be granted on the Effective Date with an exercise equal to the New Exercise price for the Repricing in order to align Mr. Dubow’s incentives with the rest of the executive officer and employees of the Company. The new stock option will vest and become exercisable on the one-yearanniversary of the Effective Date.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

                                       DAY ONE BIOPHARMACEUTICALS, INC.                     
  Date: October 10, 2025      By:      /s/ Charles N. York II, M. B. A.                     
                                       Charles N. York II, M. B. A.                         
                                       Chief Operating Officer and Chief Financial Officer